Comparative Pharmacology
Head-to-head clinical analysis: LOFEXIDINE HYDROCHLORIDE versus LUCEMYRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOFEXIDINE HYDROCHLORIDE versus LUCEMYRA.
LOFEXIDINE HYDROCHLORIDE vs LUCEMYRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alpha-2 adrenergic receptor agonist; reduces central sympathetic outflow by binding to presynaptic alpha-2 receptors in the brainstem, decreasing norepinephrine release.
LUCEMYRA (lofexidine) is a central alpha-2 adrenergic agonist that reduces the release of norepinephrine in the brain, thereby alleviating opioid withdrawal symptoms.
0.2 mg orally twice daily, titrate by 0.2-0.4 mg/day every 1-2 days to maximum 2.4 mg/day in divided doses.
18 mg orally 5-6 times daily (maximum 108 mg/day) for 7-14 days then tapered over 4-6 weeks.
None Documented
None Documented
Terminal elimination half-life is 11-13 hours in patients with normal renal function; prolonged to up to 40 hours in renal impairment.
Terminal half-life approximately 5-6 hours; no clinically significant accumulation with twice-daily dosing.
Primarily renal (approximately 80-90% as unchanged drug and metabolites, with 20-30% unchanged); minor fecal excretion (<5%).
Renal: 63% as unchanged drug; fecal: 27% (mostly unchanged); biliary: minimal (<5%).
Category C
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist